Biotech Stocks News 24 December 2025

Regencell Bioscience stock jumps 27% again as RGC’s wild swings draw momentum traders

New York, Jan 7, 2026, 10:56 EST — Regular session Regencell Bioscience Holdings Limited shares jumped about 27% to $41.90 in morning trading on Wednesday, extending a sharp two-day run for the Nasdaq-listed microcap. The stock has swung between $34.11

7 January 2026

Biotech Stocks·Stock Market

Crinetics (CRNX) shares jump as $350 million stock sale clears and early PALSONIFY revenue hits

New York, Jan 7, 2026, 11:04 EST — Regular session Shares of Crinetics Pharmaceuticals rose about 16% to $53.40 on Wednesday, after the biotech priced a $350 million stock offering and detailed early U.S. launch metrics for its newly approved

7 January 2026

Biotech Stocks·Earnings Reports·Investment Analysis·Market News·Pharma Industry

Dyne Therapeutics stock drops 5% into 2026 — FDA filing timeline and next earnings date in focus

NEW YORK, January 4, 2026, 13:49 ET — Market closed Dyne Therapeutics shares closed down 5.5% on Friday at $18.50, ending the first U.S. trading session of 2026 on a softer note. About 2.65 million shares changed hands. The pullback

4 January 2026

Biotech Stocks·Earnings Reports·FDA Updates·Investment Analysis·Market News

Wave Life Sciences (WVE) stock slides 6% — what traders are watching next

New York, Jan 4, 2026, 12:46 ET — Market closed Wave Life Sciences shares closed down 6.2% on Friday at $15.95, with the Nasdaq-listed biotech swinging between $15.53 and $17.23 in the session. The drop matters because Wave’s stock has

4 January 2026

Biotech Stocks·Investment Analysis·Market News·Stock Market·Trading Strategies

Corcept stock plunges 50% after FDA rejects relacorilant in Cushing’s-related hypertension

NEW YORK, December 31, 2025, 18:31 ET — After-hours Corcept Therapeutics Inc shares sank about 50% in after-hours trading on Wednesday after the U.S. Food and Drug Administration declined to approve its oral drug relacorilant for a Cushing’s-related hypertension use.

1 January 2026

Biotech Stocks·FDA News·Pharmaceutical Industry·Stock Market

Abivax stock drops today as ABVX traders trim Eli Lilly takeover bets into year-end

NEW YORK, December 31, 2025, 11:19 ET — Regular session Abivax Société Anonyme’s U.S.-listed American depositary shares (ABVX) fell about 3.8% to $133.04, down roughly $5.30 from Tuesday’s close, in late morning trade on Wednesday. The shares opened at $138

31 December 2025

Biotech Stocks·Mergers and Acquisitions·Pharmaceutical Industry·Stock Analysis

Why Caris Life Sciences (CAI) stock is down today as biotech slips

NEW YORK, December 30, 2025, 14:58 ET — Regular session Caris Life Sciences shares were down about 1.8% at $27.44 as of 2:41 p.m. ET, after trading between $27.00 and $27.97 during Tuesday’s session. The drop came as biotech stocks

30 December 2025

Biotech Stocks·Investing·Market Analysis

Mineralys Therapeutics (MLYS) stock slides today as biotech weakens; FDA filing timeline in focus

NEW YORK, December 30, 2025, 13:38 ET — Regular session Shares of Mineralys Therapeutics Inc fell 3.3% to $35.61 by early afternoon on Tuesday, after touching a session low of $35.17. About 513,000 shares had changed hands, versus a previous

30 December 2025

Biotech Stocks·FDA News·Investment Analysis·Pharmaceutical Industry·Stock Market

Zenas BioPharma (ZBIO) stock steadies in premarket after 8% slide as INDIGO trial timing stays in focus

NEW YORK, December 30, 2025, 09:17 ET — Premarket Zenas BioPharma, Inc. shares were flat in premarket trading on Tuesday, with the stock last indicated at $39.05 as of 9:00 a.m. ET. The biotech closed down 8.1% on Monday. Public

30 December 2025

Biotech Stocks·Clinical Trials·Stock Market

Vera Therapeutics (VERA) Stock Dips in Thin Post‑Christmas Trading as Wall Street Weighs FDA Filing, $300M Raise, and IgA Nephropathy Competition

Friday, December 26, 2025, 11:17 a.m. ET in New York. In that context—a quiet, low‑liquidity post‑Christmas session with major U.S. indexes hovering near record highs—Vera Therapeutics, Inc. (Nasdaq: VERA) is trading lower midday. Reuters and the AP both describe today’s

26 December 2025

Biotech Stocks·FDA News·Market Analysis

Omeros (OMER) Stock Surges After FDA Approval of Yartemlea: Latest News, Analyst Forecasts, and 2026 Outlook

December 25, 2025 — Omeros Corporation (NASDAQ: OMER) is having the kind of week biotech investors daydream about: a long-awaited U.S. regulatory win, a sharp stock re-rating, and a sudden pivot from “development-stage hope” to “commercial-stage execution.” The spark was

25 December 2025

Analyst Forecasts·Biotech Stocks·FDA Approvals·Investment Trends·Stock Market News

Dynavax Technologies (DVAX) Stock After the Bell on Dec. 24, 2025: Sanofi’s $2.2B Buyout, After‑Hours Action, and What to Watch Before the Next Market Open

Dynavax Technologies Corporation (NASDAQ: DVAX) is the standout mover heading into the Christmas break after Sanofi agreed to acquire the vaccine maker in an all-cash deal valued at about $2.2 billion. The transaction price — $15.50 per share in cash

24 December 2025

After-Hours Trading·Biotech Stocks·Market News·Mergers & Acquisitions·Stock Analysis

Biotech Stocks News 24 December 2025 - 7 January 2026